Statistical considerations in clinical trials testing empiric antibiotic regimens in patients with febrile neutropenia

Supportive Care in Cancer

Volumn 6, Issue 5, 1998, Pages 438-443

  Paesmans, Marianne ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Antibiotics; Chalmers score; Clinical trials; Neutropenia; Statistics

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; CLINICAL TRIAL; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; NEUTROPENIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; STATISTICAL ANALYSIS;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; FEVER; HUMANS; NEOPLASMS; NEUTROPENIA; QUALITY CONTROL; RESEARCH DESIGN;

EID: 0031695037     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050191     Document Type: Review

References (31)

1. Pocock SJ (1990) Clinical trials: a practical approach. Wiley, Chichester
2. Meinert CL (1986) Clinical trials: design, conduct and analysis. Oxford University Press, New York
3. Chalmers TC, Smith H, Blackburn B, et al (1981) A method for assessing the quality of a randomized control trial. Control Clin Trials 1:31-49
4. Pater JL, Weir L (1986) Reporting the results of randomized trials of empiric antibiotics in febrile neutropenic patients - a critical survey. J Clin Oncol 4:346-352
5. Johnson PRE, Liu Yin JA, Tooth JA (1992) A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients. J Antimicrob Chemother 30:203-214
6. Martino P, Micozzi A, Gentile G, et al (1992) Piperacillin plus amikacin versus piperacillin plus amikacin plus teicoplanin for empirical treatment of febrile episodes in neutropenic patients receiving quinolone prophylaxis. Clin Infect Dis 15:290-294
7. Ramphal R, Bolger M, Oblon DJ, et al (1992) Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 36:1062-1067
8. Rolston KV, Berkey P, Bodey GP, et al (1992) A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 152:283-291
9. Joshi JH, Newman KA, Brown BW, et al (1993) Double beta-lactam regimen compared to an aminoglycotide/beta-lactam regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients. Support Care Cancer 1:186-194
10. Micozzi A, Nucci M, Venditi M, et al (1993) Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients. Eur J Clin Microbiol Infect Dis 12:1-8
11. De Pauw BE, Deresinski SC, Feld R, et al (1994) Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med 10:835-844
12. Kojima A, Shinkai T, Soejima Y, et al (1994) A randomized prospective study of imipenem-cilastatin with or without amikacin as an empirical antibiotic treatment for febrile neutropenic patients. Am J Clin Oncol 17:400-404
13. Menichetti F, Martino P, Bucaneve G, et al (1994) Effects of teicoplanin and those of vancomycin in initial empirical regimen for febrile, neutropenic patients with hematologic malignancies. Antimicrob Agents Chemother 38:2041-2046
14. Studena M, Hlavacova E, Hel'pianska L, et al (1994) Teicoplanin plus pefioxacine versus teicoplanin plus netilmicin in empiric therapy of febrile patients with cancer and neutropenia. Chemotherapy 40:431-343
15. Freifeld A, Walsh T, Marshall D, et al (1995) Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 13:165-176
16. Meropenem Study Group of Leuven, London and Nijmegen (1995) Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 36:185-200
17. Anaissie EJ, Vartivarian S, Bodey GP, et al (1996) Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coliderived) in cancer patients with fever and neutropenia. Am J Med 100:17-23
18. Raad II, Whimbey EE, Rolston KV, Abi-Said D, et al (1996) A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients. Cancer 77:1386-1394
19. Cordonnier C, Herbrecht R, Pico JL, et al (1997) Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. Clin Infect Dis 24:41-51
20. Simon R (1994) Practical aspects of the interim monitoring of clinical trials. Stat Med 13:1401-1409
21. Byar DP, Simon RM, Friedewald WT, et al (1976) Randomized clinical trials: perspectives on some recent ideas. N Engl J Med 295:74-80
22. Chadha-Boreham H, Buyse M, Firket P, et al (1994) Minimisation as a method of allocation: a dose-effect trial in the treatment of menopause. Proceedings of the 15th meeting of the International Society for Clinical Biostatistics, 126, Basle, 1994
23. Donner A (1984) Approaches to sample size estimation in the design of clinical trials - a review. Stat Med 3:199-214
24. Blackwelder WC (1982) "Proving the null hypothesis" in clinical trials. Control Clin Trials 2:93-113
25. Braitman LE (1991) Confidence intervals assess both clinical significance and statistical significance. Ann Intern Med 114:515-517
26. Detsky AS, Sackett DL (1995) When was a "negative" trial big enough? How many patients you needed depends on what you found. Arch Intern Med 145:709-712
27. Tsiatis A (1990) Analysis and interpretation of trial results: intent-to-treat analysis. J Acquir Immune Defic Syndr 3:S120-123
28. Buyse ME (1989) Analysis of clinical trial outcomes: some comments on subgroup analyses. Control Clin Trials 10:187-194S
29. Pocock SJ (1993) Statistical and ethical issues in monitoring clinical trials. Stat Med 12:1459-1469
30. Liang KY, Zeger SL (1986) Longitudinal data analysis using generalized linear models. Biometrika 73:13-22
31. Immunocompromised Host Society (1990) The design, analysis and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis 161:397-401